Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH).
Authors
Choong-kun Lee
Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Choong-kun Lee , Han Sang Kim , Hye Jin Choi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
Registration ongoing for clinicaltrials.gov
DOI
10.1200/JCO.2022.40.4_suppl.456
Abstract #
456
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: Final analysis of a randomized phase II trial (BINGO).
First Author: David Malka
Poster
2011 ASCO Annual Meeting
Gemcitabine plus oxaliplatin (GemOx) in advanced hepatocellular carcinoma (HCC): A multicenter study of over 200 patients.
First Author: N. Williet
Poster
2013 ASCO Annual Meeting
Sorafenib (S) alone versus S combined with gemcitabine and oxaliplatin (GEMOX) in first-line treatment of advanced hepatocellular carcinoma (HCC): Final analysis of the randomized phase II GONEXT trial (UNICANCER/FFCD PRODIGE 10 trial).
First Author: Eric Assenat
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Sorafenib plus tislelizumab as maintenance therapy for patients with advanced hepatocellular carcinoma treated with transarterial chemoembolization: A phase II study.
First Author: Mingyue Cai